Chemoradiotherapy with concurrent capecitabine is a potential treatment option for select elderly or infirm patients with bladder cancer. Eleven patients with poor performance status and comorbidities with a median age of 80 years were treated with this regimen and experienced a favorable toxicity profile with high rates of local control at a median follow-up of 16 months. Background: Bladder cancer is commonly diagnosed in patients ineligible for radical cystectomy or chemoradiotherapy (chemo-RT) with cisplatin or fluorouracil with mitomycin. We assessed tolerability, efficacy, and toxicity of hypofractionated radiotherapy with capecitabine in this challenging population. Patients and Methods: Patients with high-grade urothelial bladder cancer ineligible for radical cystectomy or high-intensity chemo-RT underwent maximal transurethral resection of bladder tumor followed by capecitabine (median, 825 mg/m 2 per day 2 times a day) and radiation (median, 55 Gy in 2.2 Gy per fraction). Patients underwent surveillance cystoscopy and imaging, and were evaluated for toxicity, freedom from local failure and freedom from distant metastasis, progression-free survival, and overall survival. Results: Eleven patients (median age, 80 years) with localized disease (n ¼ 7), locally advanced disease (n ¼ 3), or local-only recurrence after cystectomy (n ¼ 1) were treated. Four patients (35%) had an Eastern Cooperative Oncology Group performance status of 2; median Charlson comorbidity index was 5. There was 1 acute grade 3 genitourinary event (9%), 6 acute grade 3 hematologic events (55%) of lymphopenia, and no acute grade 4 or higher events or hospitalizations. Ten patients (91%) completed radiotherapy, while 4 patients (36%) temporarily discontinued capecitabine. The complete response rate in the bladder was 64%. Two patients (18%) experienced late grade 1/2 genitourinary toxicities, and 1 (9%) experienced a transient late grade 4 genitourinary toxicity. With a median follow-up of 16.6 months, overall survival, progression-free survival, freedom from local failure, and freedom from distant metastasis at 1 year were 82%, 55%, 100%, and 55%, respectively, and at 2 years were 61%, 41%, 80%, and 55%, respectively. Conclusion: Hypofractionated chemo-RT was well tolerated and was associated with a high rate of local control in this comorbid population, thus providing a treatment option for select bladder cancer patients.
Introduction
Bladder cancer is the second most common genitourinary malignancy in the United States, leading to nearly 17,000 deaths in 2017. 1 With a peak incidence in patients 85 years old, bladder cancer is a disease of the elderly. 2 Although radical cystectomy and selective bladder-preserving therapy are both considered standardof-care treatment options for nonmetastatic, muscle-invasive bladder cancer (MIBC), 3 comorbidities in elderly patients may greatly increase the risk of postoperative complications and mortality from surgery. 4 Therefore, although cystectomy remains the common treatment of choice in younger patients with good performance status, 5 most elderly patients do not undergo cystectomy because of medical comorbidity, functional status, and social factors. 6 Combined-modality bladder-preserving therapy consists of maximal transurethral resection of bladder tumor followed by concurrent chemoradiotherapy (chemo-RT). Cisplatin-based doublet chemotherapy, and 5-fluorouracil (5-FU) with mitomycin (MMC) are two well-established radiosensitizing regimens. 3, 7 However, not all patients are candidates to receive these chemotherapies because of preexisting medical comorbidities or poor performance status. For such patients, single-agent capecitabine with radiotherapy (RT) may provide a more suitable therapeutic ratio. 8 This potentially milder form of chemo-RT has been provided at our institution to patients ineligible for radical cystectomy or aggressive chemotherapy. The goal of this study was to describe our initial experience regarding tolerability, efficacy, and toxicity of hypofractionated RT with capecitabine in this challenging population to add to the currently limited existing data for this regimen.
Material and Methods

Eligibility Criteria
Patients with locally advanced nonmetastatic urothelial carcinoma who were unfit for surgery or high-intensity chemo-RT with cisplatin or 5-FU/MMC based on multidisciplinary tumor board consensus (generally with Karnofsky performance status 70 or major medical comorbidity) who received maximal transurethral resection of bladder tumor (TURBT) followed by concurrent capecitabine and RT at a single academic institution were eligible for this study. Electronic medical records were reviewed retrospectively for patient and tumor characteristics, Charlson comorbidity index (CCI), 9 treatment details, toxicities, and patient outcomes.
This study received institutional review board approval from the University of Chicago (IRB17-1436).
Treatment
Maximal TURBT was performed for all patients with an intact bladder before the start of chemo-RT, and no patients received TURBTs after the initiation of chemo-RT. Patients received capecitabine at a median dose of 1500 mg/m 2 per day (range, 1050-1700 mg/m 2 ) using twice-daily dosing on all days of RT (Monday through Friday), with the last dose administered at the end of RT. One of the daily doses was provided approximately 1 hour before RT.
Computed tomography (CT)-based simulation for radiation planning was performed after completion of TURBT, with patients in the supine position with upper and lower alpha cradles used for custom immobilization. Patients voided to completion for the simulation and for daily treatment to obtain an empty bladder volume.
Three-dimensional conformal RT (n ¼ 3, 27%) or intensitymodulated radiotherapy (n ¼ 8, 73%) was delivered using 6 to 15 MV photons. The latter was mostly used for patients with suspected lymph nodeepositive disease (n ¼ 5). The planning target volume (PTV) was generally defined as the empty bladder plus a 1.5 cm margin ( Figure 1 ). An initial PTV included pelvic lymph nodes based on clinician discretion in 6 patients (55%) with either radiographic suspicion of lymph node involvement (n ¼ 5) or high-risk for involvement (n ¼ 1), and was defined as internal and external iliac vessels plus a 1.5 cm margin modified around bone and muscle ( Figure 2) , with the superior border typically at the L5/S1 junction.
The most common dose prescription to the entire bladder was 55 Gy in 2.2 Gy per fraction (fx) (n ¼ 8/11, 73%; range, 45-64 Gy at 2.0-2.25 Gy/fx). This slightly hypofractionated regimen was chosen because of its comparable biologically equivalent dose with the BC2001 55 Gy/20 fx, 5 published tolerability with concurrent capecitabine for pelvic malignancies, 10, 11 and ease of matching pelvic nodal RT dosing over the same 25 days of therapy. The most common dose provided to the pelvic lymphatics was 45 to 50 Gy in Figure 1 Representative RT Initial treatment planning directives were adapted from previous prospective studies. 12, 13 More than 99% of the PTV received at least 95% of the prescription dose (V 95% > 99%) with less than 10% of the PTV receiving 105% (V 105% < 10%) and no volume receiving greater than 115% of the prescription dose. Organs at risk and dose constraints included small bowel (V 45 < 90 mL, V 40 < 130 mL, V 35 < 230 mL), rectum (V 30 < 50%, V 55 < 10%, posterior half < 80% total dose), and femoral heads (V 50 < 20%). Image guidance for setup verification was performed using daily kilovoltage and cone beam CT to verify that pelvic nodal volumes and the bladder were within the PTV.
Toxicity and Treatment Response
Treatment-related toxicities were recorded prospectively at each clinical evaluation by the treating physician using Common Terminology Criteria for Adverse Events, version 4.0, toxicity grading criteria. Acute toxicities were defined as toxicities during treatment and within 90 days of treatment completion. Late toxicities were defined as toxicities occurring 90 days after treatment. Laboratory-related toxicities were evaluated for the duration of treatment only. Clinical findings, imaging reports, and cystoscopy results were used to classify treatment response as complete or partial. A complete response was defined as an absence of tumor on cystoscopy, normal cytology, and no evidence of disease on CT, and a partial response was defined as any response on cystoscopy, normal cytology, or CT. Stable disease was defined as no interval response on first cystoscopy or CT, and no response was defined as disease progression at first cystoscopy or CT. Overall response was defined as complete responses plus partial responses.
Follow-up and Statistical Analysis
Patients were generally followed by a multidisciplinary group at 3-month intervals with physical examinations, cystoscopy, cytology, and surveillance CT scans for the first 2 years after therapy, followed by 6-month intervals thereafter. Descriptive statistics were generated through retrospective review of electronic medical records. Overall survival (OS), progression-free survival, freedom from local failure, and freedom from distant metastasis were estimated by KaplanMeier survival analysis using GraphPad Prism 7.0a software (GraphPad Software, La Jolla, CA).
Results
Patient and Tumor Characteristics
Between April 2012 and August 2016, 20 patients were referred to the radiation oncology department at a single academic institution for curative-intent chemo-RT. Eleven patients (55%) with locally advanced nonmetastatic bladder cancer were thought to be unfit for standard chemo-RT with cisplatin or 5-FU/MMC on the basis of multidisciplinary discussion, and they were treated with maximal TURBT followed by concurrent capecitabine and RT ( Table 1 ). The median age was 80 years (range, 63-87 years), and 10 (91%) of 11 patients were more than 78 years old. The majority of patients were male (n ¼ 8, 73%), white (n ¼ 6, 55%), and current or prior smokers (n ¼ 8, 73%). The median CCI in these patients (excluding points for solid tumor) was 5 (range, 3-7), and 4 (35%) of 11 patients had an Eastern Cooperative Oncology Group performance status of 2.
Two patients had received a prior nephroureterectomy, and one patient received a prior cystoprostatectomy with ileal conduit, and was treated for recurrence in the cystectomy bed. The median number of TURBTs before the start of treatment was 1 (range, [1] [2] [3] [4] [5] , and the median time between the last resection (either surgery or TURBT) and RT was 1.9 months. Three patients received prior intravesical therapy, either with mitomycin C (n ¼ 1), bacillus Calmette-Guérin (BCG) vaccine (n ¼ 1), or BCG followed by gemcitabine (n ¼ 1). No patients received neoadjuvant chemotherapy. Six patients had localized muscle-invasive disease (T2-T4N0), 1 patient had nonemuscle-invasive disease (T1N0) and underwent chemo-RT and was provided 5 prior TURBTs and multiple cycles of intravesicular chemotherapy, 3 patients had locally advanced disease (T2-3N1-2), and 1 patient had recurrent disease in the cystectomy bed. All patients had high-grade urothelial carcinoma and were treated with curative intent.
Capecitabine and RT
Patients received concurrent capecitabine with RT for a median of 5 weeks (range, 3.9-6.4 weeks). Seven patients (64%) completed the planned course of capecitabine, and 4 patients (36%) required discontinuation or interruptions due to diarrhea (n ¼ 2, for 2 and 7 days, respectively), hyperbilirubinemia (n ¼ 1, for 4 days), or hospitalization for preexisting cardiac disease (n ¼ 1, for 17 days). Of these 4 patients, 3 completed RT after stopping capecitabine.
Toxicities and Hospitalizations
Acute and late toxicities are summarized in Table 2 . During the course of treatment, there was one grade 3 nonhematologic toxicity consisting of severe urinary urgency leading to catheter placement for 1 week and discontinuation of RT during the last week of treatment. No grade 4 nonhematologic toxicity was observed. Furthermore, no clinically significant hematologic toxicities were observed; the only cases of grade 3 hematologic toxicity included lymphopenia, and there were no grade 3 or higher neutropenia events.
One patient was hospitalized during treatment for grade 2 atrial fibrillation resulting from underlying cardiac disease and went on to complete RT without capecitabine after medical management of the atrial fibrillation. Furthermore, 3 patients required hospitalizations in the 3 months immediately after treatment. The reasons for hospitalization included concern for bladder perforation after surveillance TURBT, which was ultimately ruled out by CT (n ¼ 1), lower extremity edema and pain (n ¼ 1), and urinary tract infection in the setting of catheter placement with readmission 2 weeks later for aspiration pneumonia (n ¼ 1).
No late gastrointestinal toxicity was observed. Three patients (27%) experienced late genitourinary toxicities, including one grade 4 radiation cystitis 18 months after the completion of treatment, which required a transfusion for 2 units of red blood cells and fulguration of a vessel in a bladder diverticulum.
Treatment Response and Outcomes
Responses to treatment and clinical outcomes are listed in Table 3 . No disease progression was observed during therapy. Median followup was 16.6 months (range, 1.6-44.9 months). The overall response rate in the bladder was 9 (82%) of 11 according to surveillance cystoscopy with imaging (n ¼ 8), or imaging alone (n ¼ 3) within 3 months of treatment completion. In the 8 patients who underwent cystoscopy, 7 had complete response of disease. Five (45%) of these patients with complete response, including both suspected nodepositive patients in this cohort, experienced long-term complete remissions for a median of 28 months and were without disease at last follow-up. One delayed local failure was observed 21 months after treatment in a patient who had experienced complete clinical response by cystoscopy. This local relapse was salvaged with repeat TURBT and intravesical BCG. Five patients (45%) developed metastasis at a median of 3 months to the lung (n ¼ 3) or peritoneum (n ¼ 2).
The OS, progression-free survival, freedom from local failure, and freedom from distant metastasis at 1 year were 82%, 55%, 100%, and 55% respectively, and at 2 years were 61%, 41%, 80%, and 55%, respectively ( Figure 3 ).
Discussion
In this study, we adopted a bladder-sparing approach using maximal TURBT followed by concurrent chemo-RT with capecitabine in an elderly patient population with a median age of 80 years. Treatment was well tolerated, with minimal acute or late severe toxicity, and a high rates of local control was observed at 2 years after treatment. Despite the small sample size, these favorable results warrant further prospective investigation of concurrent capecitabine and RT for select patients with MIBC who may not be candidates for other potentially curative therapies, including radical cystectomy or more aggressive chemoradiotherapy regimens. 
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Several biologic considerations provide the rationale for use of capecitabine as a radiosensitizing agent in the treatment of MIBC. Capecitabine is preferentially converted to 5-FU in urothelial carcinoma, providing selectivity for tumor cells.
14 Furthermore, radiation offers synergistic effects on the intracellular activation of capecitabine through the up-regulation of thymidine phosphorylase, which may provide greater efficacy at lower and less toxic doses. 15 In regards to clinical data, to our knowledge, only one other study has reported on the use of concurrent capecitabine and radiation in MIBC. Patel et al 8 also included a small cohort of patients (n ¼ 14)
ineligible for platinum-based chemotherapies and demonstrated results consistent with our study in terms of tolerability and efficacy, including no grade 4/5 toxicities, a 20% hospitalization rate, complete clinical response in 77% of patients, and only 3 of 11 patients with response and relapse at a median follow-up of 10.5 months. We undertook our study to verify the efficacy and safety of this regimen, seeking to expand on their report by including detail regarding RT planning, disease outcome, and toxicity. Another recent effort to identify a concurrent chemotherapy regimen in patients not suitable for cisplatin-based chemotherapy includes RTOG 0524, a phase 1/2 trial of either combination paclitaxel and trastuzumab or paclitaxel alone after TURBT in 68 MIBC patients. 16 Acute grade 2 or higher treatment-related adverse events were observed in 7 (35%) of 20 patients in the paclitaxel þ trastuzumab arm (group 1) and 14 (30.4%) of 46 patients in the paclitaxel-alone arm (group 2). The majority of adverse events were gastrointestinal, including one grade 5 adverse event in group 1. Furthermore, the complete response rate at 1 year was 72% for group 1% and 68% for group 2, suggesting this regimen is an effective treatment strategy. Concurrent gemcitabine has also been studied as a radiosensitizing agent. A phase 2 trial tested either 5-FU/cisplatin or gemcitabine with radiation in 66 patients with MIBC. 13 Acute grade 3/4 events were observed in 21 (64%) of 33 patients in the 5-FU/cisplatin arm, and in 18 (55%) of 33 patients in the gemcitabine arm. Both regimens in this study had high rates of metastasis-free survival at 3 years-67% and 72%, respectively. A phase 1 study of 24 patients treated with 60 Gy and twice-weekly gemcitabine reported a 91% rate of complete response, diseasespecific survival of 82% at 5 years, and 30% local and 22% distant failure. 17 Although it is not possible to make valid comparisons of our results to these prospective studies, the response rates and disease outcomes of capecitabine with RT in our study do not appear to be strikingly less effective or more toxic in what is likely to be a much less favorable patient population. The encouraging findings of the current and aforementioned studies are of particular importance, given that the availability of a more tolerable, curative-intent chemo-RT treatment option may lessen the underutilization of definitive treatment and overutilization of suboptimal therapies such as radiation alone for MIBC as a result of concerns of toxicity, 18 particularly in older age groups. The superiority of chemo-RT over RT alone in this setting is well established in the literature, including results of the phase 3 BC2001 trial, which randomized patients with MIBC who completed TURBT to either RT alone or chemo-RT with 5-FU/MMC and demonstrated improved 2-year locoregional disease-free survival of 67% in the chemo-RT group versus 54% in the RT-alone group. A second study performed by the National Cancer Institute of Canada randomized patients with MIBC to RT alone versus with concurrent cisplatin, and reported fewer recurrences in the pelvis in the chemo-RT group (15/51 patients) versus the RT-alone group (25/48 patients). Notably, elderly and medically infirm patients with bladder cancer were 7 and a maximum eligibility age of 76 years in the study performed by National Cancer Institute of Canada. 19 Thus, further exploration of an alternative concurrent chemotherapy regimen in this population is needed to optimize the therapeutic ratio.
Retrospective data from large databases reaffirm the value of pursuing potentially curative chemo-RT over either modality alone or neither modality. In a National Cancer Data Base (NCDB) analysis of 1783 patients with clinically node-positive bladder cancer, median OS with chemo-RT was 19 months compared to 13.8 months with chemotherapy alone. Another recent NCDB analysis including 1369 patients 80 years of age with MIBC reported the 2-year OS for chemo-RT to be 56% compared to 42% with RT (60-70 Gy) alone. 20, 21 Furthermore, in a NCDB analysis of patients aged 75 treated for MIBC with radical cystectomy (21%), chemo-RT (13%), or neither (66%), 22 median survival was significantly shorter in patients receiving neither therapy (12 months, compared to 26.5 months for cystectomy and 22.1 months for chemo-RT). In the subset of patients with CCI > 1, median survival was longer for those receiving chemo-RT (15.9 months) compared to cystectomy (12.5 months) or neither (6.4 months), though this finding is subject to patient selection bias. Collectively, these large data sets further support the use of chemo-RT within a bladder-conserving treatment paradigm for MIBC patients, even for elderly patients who may be subject to greater comorbidities and poor performance status than younger patients. Although this study provides encouraging results on initial toxicity and efficacy with the use of concurrent capecitabine and radiation after TURBT, there are several limitations of our study, including its small sample size, retrospective design, and potential for patient selection bias to influence outcomes. As a retrospective study, it was not possible to describe exact criteria to classify patients as unfit for more standard therapy. Furthermore, competing risks of mortality have limited the length of follow-up time, making it difficult to estimate longer-term control rates. Ideally, future prospective comparative studies will be conducted to validate our findings and to better understand which patients are likely to benefit most from this reduced-intensity chemo-RT regimen. Future studies may focus on molecular subtyping to offer additional guidance on proper patient selection and prediction of treatment response of MIBC to various chemo-RT regimens. 23 
Conclusion
For well-selected elderly patients, chemo-RT with capecitabine is a tolerable regimen with effective local control that may increase the utilization of definitive treatment for MIBC. Patient characteristics such as poor performance status, renal failure, and other comorbidities are essential to guide clinical decision making regarding eligibility for therapy.
Clinical Practice Points
Elderly patients are less likely to receive definitive treatment for MIBC with radical cystectomy or chemo-RT with concurrent cisplatin or mitomycin. Hypofractionated chemo-RT with concurrent capecitabine may offer a more appropriate therapeutic ratio for this population while preserving bladder function. We conducted this study to evaluate the tolerability and outcomes of this combination in 11 elderly patients with poor performance status or medical comorbidity. Chemo-RT resulted in low numbers of high-grade toxicities in the acute and late setting with high rates of local control. The encouraging results of this series support the need for larger prospective studies of hypofractionated chemo-RT with capecitabine in select elderly patients who are unfit for more aggressive therapies.
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